Group b streptococcus identification and drug susceptibility testing card, group b streptococcus identification and drug susceptibility testing kit and methods of using the same

Abstract

The invention discloses an identification and drug sensitivity test card for group B streptococcus, an identification and drug sensitivity test kit for the group B streptococcus and a using method of the identification and drug sensitivity test kit for the group B streptococcus. The identification and drug sensitivity test card for the group B streptococcus comprises a test card body, wherein an identification micropore area and a drug sensitivity test area are arranged on the test card body; the identification micropore area is provided with a plurality of identification micropores; the drug sensitivity test area is provided with a plurality of drug sensitivity micropores. According to the identification and drug sensitivity test card for the group B streptococcus disclosed by the invention, an identification experiment and a drug sensitivity test experiment on the group B streptococcus can be carried out at the same time, and the convenience is better. Based on a display method / a turbidimetric method, identification and drug sensitivity experiments on the group B streptococcus are carried out; compared with nucleic acid test, the test cost is lower.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a group B streptococcus identification and drug sensitivity detection card, a group B streptococcus identification and drug sensitivity detection kit and a use method thereof. Background technique [0002] Group B streptococcus (GBS), also known as S. agalactiae, was first discovered in 1938. In 1938, Fry first reported three cases of postpartum endocarditis caused by group B streptococcus infection. Death, confirming that group B streptococci are pathogenic bacteria in humans. After the development of science and technology, it was found that group B streptococcus can cause neonatal sepsis, pneumonia, meningitis, and even death. Neonates who survive infection may also have severe neurological sequelae, including hydrocephalus, intellectual disability, microcephaly, and deafness. At the same time, Group B Streptococcus can also cause infection in pregnant women, premature d...

AI Technical Summary

Problems solved by technology

[0005] At present, the identification methods of Group B Streptococcus include: (1) microbial plate culture method, which is complicated to operate, requires professionals, and is time-consuming and laborious; (2) antigen gold standard detection method, which has poor sensitivity and specificity , the experimental results have a low degree of conformity with the clinic, and it is difficult to meet the needs of the hospital; (3) Molecular probe detection method, which requires high test conditions, and the test operation is complicated, requiring expensive equipment and professionals to complete

GBS drug susceptibility test method is mainly the disk diffusion method, which is relatively simple, but it takes too long to perform quantitative detection

In summary, the current identification and drug susceptibility testing methods for GBS are difficult to meet the fast, simple, accurate and reliable requirements required by the hospital.

In addition, the existing chromogenic method / turbidimetric method for identification and drug susceptibility testing of Group B Streptococcus needs to do Group B Streptococcus identification test first, after Group B Streptococcus is identified as positive, then carry out B Streptococcus test. The drug susceptibility test of Streptococcus group is time-consuming and labor-intensive, and the convenience is poor

Images